Southeast AIDS Education and Training Center (SE AETC) | 615-875-7873

Webinar: HPTN083 Injectable Cabotegravir for PrEP

HIV Prevention, Webcast

Objectives

  • To understand the differences between currently approved PrEP and long acting injectable agents
  • To describe the conduct and outcome of the HPTN 083 study
  • To discuss advantages/disadvantages of currently available and soon to be available PrEP options

Presentation

Slides

Facilitated by Rachel Presti, MD, PhD
Washington University School of Medicine
September 9, 2020

Objectives

  • To understand the differences between currently approved PrEP and long acting injectable agents
  • To describe the conduct and outcome of the HPTN 083 study
  • To discuss advantages/disadvantages of currently available and soon to be available PrEP options

Presentation

Slides

Facilitated by Rachel Presti, MD, PhD
Washington University School of Medicine
September 9, 2020

Objectives

  • To understand the differences between currently approved PrEP and long acting injectable agents
  • To describe the conduct and outcome of the HPTN 083 study
  • To discuss advantages/disadvantages of currently available and soon to be available PrEP options

Presentation

Slides